Video

Zanubrutinib Demonstrates Superior Progression-Free Survival Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Results from Final Analysis of ALPINE Randomized Phase 3 Study

Author(s):

Nicole Lamanna, MD

Nicole Lamanna, MD, reviews the results of the phase 3 study evaluating the use of zanubrutinib versus ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Related Videos
A panel of 3 experts on CLL
A panel of 3 experts on CLL
Moritz Fürstenau, MD
Mazyar Shadman, MD, MPH
Management of Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoietin Stimulating Agent (ESA) Treatment
A panel of 3 experts on CLL
A panel of 3 experts on CLL
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Tycel Phillips, MD
Moritz Fürstenau MD, Division of Haematology, Immunology, Infectiology, Intensive Care, and Oncology, University of Cologne
Related Content
Yucai Wang, MD, PhD, Mayo Clinic
July 22nd 2024

Pembrolizumab Plus B-Cell Receptor Inhibitors Generates Responses in Richter Transformation of CLL/SLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Orelabrutinib Plus FCG Generates Rapid Molecule Remissions in CLL
July 3rd 2024

First-Line Orelabrutinib Plus FCG Generates Rapid Molecule Remissions in CLL

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Arliene Ravelo Mangalindan, MPH, director, Oncology Health Economics & Outcomes Research, Genentech
June 18th 2024

Patients With CLL Place the Most Value on Treatments That Prolong PFS

Stephen Opat, of Monash Health
June 17th 2024

Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL